patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_536172 | REC_0013101 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 13.1 | 62 | male | 1 | 26 | 5.2 | 2 | entrectinib 600 mg daily | 25.6 | true | MSS | 2026-03-15T05:36:00.256872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824581 | REC_0013102 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 7 | 62 | female | 1 | 80 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.5 | true | MSS | 2026-03-15T05:36:00.257235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_131380 | REC_0013103 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 7.4 | 47 | male | 0 | 10 | 6.8 | 5 | osimertinib 80 mg daily | 12.8 | true | MSS | 2026-03-15T05:36:00.257594+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725152 | REC_0013104 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 4.8 | 59 | male | 0 | 39 | 6 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.8 | true | MSS | 2026-03-15T05:36:00.257959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320304 | REC_0013105 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 12.6 | 76 | female | 1 | 14 | 4.3 | 1 | alectinib 600 mg BID | 11.1 | true | MSS | 2026-03-15T05:36:00.258499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_160396 | REC_0013106 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 7.4 | 75 | female | 1 | 13 | 8.3 | 3 | osimertinib 80 mg daily | 29.6 | false | MSS | 2026-03-15T05:36:00.258866+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474668 | REC_0013107 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 36 | 10.7 | 69 | male | 0 | 19 | 7.5 | 4 | alectinib 600 mg BID | 7.8 | true | MSI-H | 2026-03-15T05:36:00.259208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_472226 | REC_0013108 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 11.1 | 84 | female | 2 | 15 | 4.6 | 2 | pembrolizumab 200 mg q3w | 21.9 | false | MSS | 2026-03-15T05:36:00.259551+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583662 | REC_0013109 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 12.8 | 70 | female | 2 | 18 | 6.2 | 5 | entrectinib 600 mg daily | 15.5 | false | MSI-H | 2026-03-15T05:36:00.259872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988122 | REC_0013110 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 8.4 | 76 | male | 3 | 20 | 5.8 | 1 | entrectinib 600 mg daily | 24 | false | MSS | 2026-03-15T05:36:00.260327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177394 | REC_0013111 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 11.5 | 67 | female | 1 | 13 | 4.5 | 2 | alectinib 600 mg BID | 14.6 | false | MSI-H | 2026-03-15T05:36:00.260672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103205 | REC_0013112 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 8.4 | 52 | male | 0 | 6 | 3.8 | 2 | sotorasib 960 mg daily | 12.4 | true | MSS | 2026-03-15T05:36:00.260964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556468 | REC_0013113 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 5.6 | 66 | female | 0 | 47 | 4.4 | 8 | carboplatin + paclitaxel + pembrolizumab | 7.4 | false | MSS | 2026-03-15T05:36:00.261243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786176 | REC_0013114 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.3 | 62 | female | 0 | 15 | 5.9 | 6 | osimertinib 80 mg daily | 12.3 | true | MSI-H | 2026-03-15T05:36:00.261517+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364731 | REC_0013115 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 13 | 70 | female | 1 | 15 | 6.9 | 2 | sotorasib 960 mg daily | 19 | false | MSS | 2026-03-15T05:36:00.261809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536589 | REC_0013116 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 30 | 12.4 | 60 | female | 0 | 13 | 6.8 | 2 | pembrolizumab 200 mg q3w | 17.9 | true | MSI-H | 2026-03-15T05:36:00.262103+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_405148 | REC_0013117 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 10.9 | 78 | male | 1 | 20 | 6.5 | 6 | pembrolizumab 200 mg q3w | 7.6 | true | MSS | 2026-03-15T05:36:00.262380+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272483 | REC_0013118 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 9.2 | 75 | female | 2 | 14 | 5.4 | 0 | pembrolizumab 200 mg q3w | 43.1 | true | MSS | 2026-03-15T05:36:00.262773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710107 | REC_0013119 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 13 | 56 | female | 1 | 12 | 5.5 | 5 | sotorasib 960 mg daily | 10.6 | false | MSS | 2026-03-15T05:36:00.263092+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456598 | REC_0013120 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 8.6 | 70 | female | 2 | 35 | 7.3 | 2 | pembrolizumab 200 mg q3w | 10 | false | MSS | 2026-03-15T05:36:00.263371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_769117 | REC_0013121 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 7.1 | 65 | male | 1 | 9 | 5.7 | 7 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:36:00.263699+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138871 | REC_0013122 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 9.6 | 68 | male | 0 | 17 | 5.3 | 1 | alectinib 600 mg BID | 5.8 | true | MSS | 2026-03-15T05:36:00.263996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422335 | REC_0013123 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 40 | 6.8 | 71 | female | 1 | 36 | 6.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.3 | true | MSS | 2026-03-15T05:36:00.264373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456567 | REC_0013124 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 13.9 | 55 | male | 1 | 23 | 4.5 | 7 | pembrolizumab 200 mg q3w | 9.6 | true | MSI-H | 2026-03-15T05:36:00.264712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260019 | REC_0013125 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11.2 | 60 | female | 0 | 14 | 5 | 6 | alectinib 600 mg BID | 11.5 | false | MSI-H | 2026-03-15T05:36:00.265043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465445 | REC_0013126 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 9.6 | 88 | female | 2 | 17 | 4.7 | 5 | alectinib 600 mg BID | 9.5 | false | MSS | 2026-03-15T05:36:00.265388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811021 | REC_0013127 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.2 | 72 | male | 1 | 3 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.6 | false | MSS | 2026-03-15T05:36:00.265732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614937 | REC_0013128 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.6 | 67 | male | 0 | 33 | 5.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 16 | false | MSS | 2026-03-15T05:36:00.266062+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847070 | REC_0013129 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 25 | 12.3 | 69 | female | 1 | 20 | 5.1 | 0 | sotorasib 960 mg daily | 47.2 | true | MSI-H | 2026-03-15T05:36:00.266372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591830 | REC_0013130 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 3.8 | 66 | female | 0 | 38 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.1 | false | MSS | 2026-03-15T05:36:00.266674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525518 | REC_0013131 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 9 | 69 | female | 0 | 16 | 5.5 | 1 | osimertinib 80 mg daily | 11.6 | false | MSS | 2026-03-15T05:36:00.267184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985273 | REC_0013132 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 17.5 | 71 | female | 1 | 26 | 5.8 | 6 | sotorasib 960 mg daily | 10.8 | true | MSS | 2026-03-15T05:36:00.267526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_217714 | REC_0013133 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 13.6 | 64 | female | 1 | 19 | 4.1 | 3 | sotorasib 960 mg daily | 12.7 | false | MSI-H | 2026-03-15T05:36:00.267833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219887 | REC_0013134 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 36 | 8.2 | 65 | male | 1 | 11 | 6.1 | 0 | entrectinib 600 mg daily | 17.1 | false | MSS | 2026-03-15T05:36:00.268187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_129028 | REC_0013135 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 14.5 | 73 | female | 2 | 14 | 5.3 | 3 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:00.268577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_950640 | REC_0013136 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 12 | 8.2 | 74 | female | 2 | 18 | 7 | 5 | pembrolizumab 200 mg q3w | 15.9 | false | MSS | 2026-03-15T05:36:00.268951+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988816 | REC_0013137 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.2 | 83 | female | 2 | 3 | 5.3 | 9 | sotorasib 960 mg daily | 18.4 | false | MSI-H | 2026-03-15T05:36:00.269328+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247238 | REC_0013138 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 6.3 | 66 | female | 0 | 19 | 4.2 | 1 | sotorasib 960 mg daily | 26.5 | true | MSS | 2026-03-15T05:36:00.269704+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198943 | REC_0013139 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 15.8 | 52 | male | 0 | 14 | 3.3 | 4 | entrectinib 600 mg daily | 17.4 | false | MSI-H | 2026-03-15T05:36:00.270072+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_447250 | REC_0013140 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 8.3 | 62 | female | 0 | 17 | 5.1 | 5 | osimertinib 80 mg daily | 14 | false | MSS | 2026-03-15T05:36:00.270413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554971 | REC_0013141 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 10.7 | 63 | female | 1 | 11 | 4.9 | 7 | osimertinib 80 mg daily | 6 | false | MSS | 2026-03-15T05:36:00.270732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863809 | REC_0013142 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 10.9 | 56 | female | 0 | 23 | 3.6 | 0 | entrectinib 600 mg daily | 27.8 | true | MSI-H | 2026-03-15T05:36:00.271044+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679618 | REC_0013143 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 16 | 59 | male | 0 | 12 | 4.3 | 6 | osimertinib 80 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:36:00.271388+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879023 | REC_0013144 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 19 | 15.2 | 71 | female | 1 | 15 | 5.7 | 0 | osimertinib 80 mg daily | 47.3 | false | MSS | 2026-03-15T05:36:00.271847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498792 | REC_0013145 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 12 | 51 | male | 0 | 19 | 5.3 | 5 | osimertinib 80 mg daily | 9 | true | MSS | 2026-03-15T05:36:00.272252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594848 | REC_0013146 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 11.5 | 52 | female | 0 | 15 | 5.5 | 7 | osimertinib 80 mg daily | 9.9 | false | MSS | 2026-03-15T05:36:00.272619+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252155 | REC_0013147 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 2.1 | 60 | male | 1 | 32 | 5.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 12.6 | true | MSS | 2026-03-15T05:36:00.272982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294417 | REC_0013148 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 7.9 | 56 | male | 0 | 46 | 6.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 18.2 | false | MSS | 2026-03-15T05:36:00.273321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648726 | REC_0013149 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 14 | 18.1 | 63 | female | 0 | 14 | 5.9 | 1 | osimertinib 80 mg daily | 18 | false | MSS | 2026-03-15T05:36:00.273633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_917256 | REC_0013150 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 7.6 | 83 | female | 2 | 12 | 6 | 1 | osimertinib 80 mg daily | 24.5 | true | MSS | 2026-03-15T05:36:00.273917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780073 | REC_0013151 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 12.2 | 67 | female | 0 | 17 | 5 | 8 | sotorasib 960 mg daily | 6.6 | true | MSI-H | 2026-03-15T05:36:00.274207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995276 | REC_0013152 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 17.8 | 71 | female | 1 | 9 | 5.5 | 7 | entrectinib 600 mg daily | 8.6 | false | MSS | 2026-03-15T05:36:00.274488+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_729496 | REC_0013153 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 12.6 | 70 | female | 2 | 13 | 6.8 | 5 | osimertinib 80 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:36:00.274766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616380 | REC_0013154 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 14.5 | 66 | male | 0 | 16 | 6.2 | 6 | osimertinib 80 mg daily | 12.7 | true | MSS | 2026-03-15T05:36:00.275046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193158 | REC_0013155 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 20 | 11.2 | 55 | male | 0 | 23 | 5.6 | 2 | pembrolizumab 200 mg q3w | 16.9 | false | MSS | 2026-03-15T05:36:00.275329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_625068 | REC_0013156 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 5.7 | 70 | female | 2 | 50 | 3.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.6 | false | MSS | 2026-03-15T05:36:00.275616+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291358 | REC_0013157 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 11 | 13.1 | 58 | female | 0 | 7 | 4.7 | 6 | osimertinib 80 mg daily | 15.7 | false | MSS | 2026-03-15T05:36:00.276233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589045 | REC_0013158 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 13.6 | 80 | female | 1 | 30 | 7.2 | 2 | sotorasib 960 mg daily | 28.8 | true | MSI-H | 2026-03-15T05:36:00.276641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794213 | REC_0013159 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 9.9 | 65 | male | 0 | 20 | 5.4 | 6 | alectinib 600 mg BID | 8 | false | MSS | 2026-03-15T05:36:00.276960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410374 | REC_0013160 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 8.8 | 74 | female | 2 | 11 | 5.1 | 4 | alectinib 600 mg BID | 6.4 | false | MSS | 2026-03-15T05:36:00.277256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_337335 | REC_0013161 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.4 | 61 | male | 1 | 23 | 3.8 | 9 | sotorasib 960 mg daily | 5.9 | false | MSS | 2026-03-15T05:36:00.277576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844192 | REC_0013162 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.2 | 73 | female | 2 | 27 | 5.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.9 | false | MSS | 2026-03-15T05:36:00.277899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_708028 | REC_0013163 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 13.7 | 66 | female | 1 | 16 | 4.8 | 1 | entrectinib 600 mg daily | 14.5 | false | MSI-H | 2026-03-15T05:36:00.278257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508592 | REC_0013164 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 3 | 79 | female | 2 | 12 | 5.5 | 4 | alectinib 600 mg BID | 13.4 | true | MSS | 2026-03-15T05:36:00.278606+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_512409 | REC_0013165 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 4.9 | 70 | female | 1 | 16 | 3.9 | 6 | pembrolizumab 200 mg q3w | 15.7 | true | MSS | 2026-03-15T05:36:00.278945+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170110 | REC_0013166 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 6.1 | 79 | female | 2 | 21 | 5.4 | 3 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:36:00.279252+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_164828 | REC_0013167 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 1.6 | 56 | female | 1 | 46 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.9 | true | MSS | 2026-03-15T05:36:00.279566+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_341534 | REC_0013168 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 11.7 | 70 | female | 1 | 3 | 4.9 | 7 | osimertinib 80 mg daily | 6.1 | true | MSS | 2026-03-15T05:36:00.279863+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501695 | REC_0013169 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 10.7 | 71 | female | 1 | 17 | 4.5 | 7 | alectinib 600 mg BID | 5.3 | false | MSS | 2026-03-15T05:36:00.280273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587256 | REC_0013170 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 12.2 | 72 | female | 0 | 6 | 4.2 | 1 | alectinib 600 mg BID | 21.5 | true | MSS | 2026-03-15T05:36:00.280771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_168773 | REC_0013171 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 1.5 | 67 | female | 0 | 37 | 5.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 29.2 | true | MSS | 2026-03-15T05:36:00.281137+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839815 | REC_0013172 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 17 | 15.5 | 61 | female | 1 | 17 | 4.1 | 4 | osimertinib 80 mg daily | 11.8 | false | MSS | 2026-03-15T05:36:00.281483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849400 | REC_0013173 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 35 | 10.9 | 67 | female | 0 | 15 | 4.9 | 1 | entrectinib 600 mg daily | 19.8 | true | MSI-H | 2026-03-15T05:36:00.281835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_714178 | REC_0013174 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 18.2 | 48 | female | 0 | 13 | 7 | 4 | osimertinib 80 mg daily | 10.6 | false | MSS | 2026-03-15T05:36:00.282321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364802 | REC_0013175 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 13.3 | 61 | female | 0 | 15 | 5.2 | 5 | alectinib 600 mg BID | 4 | true | MSI-H | 2026-03-15T05:36:00.282710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710968 | REC_0013176 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 9.8 | 56 | male | 1 | 15 | 4.4 | 6 | entrectinib 600 mg daily | 15.5 | true | MSS | 2026-03-15T05:36:00.283012+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956805 | REC_0013177 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 4.4 | 81 | male | 3 | 56 | 3.8 | 3 | carboplatin + paclitaxel + pembrolizumab | 17.6 | true | MSS | 2026-03-15T05:36:00.283324+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395569 | REC_0013178 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 15 | 6.5 | 73 | female | 3 | 28 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.7 | true | MSS | 2026-03-15T05:36:00.283641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672693 | REC_0013179 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 9.8 | 60 | female | 1 | 12 | 5.8 | 7 | alectinib 600 mg BID | 9.3 | true | MSS | 2026-03-15T05:36:00.283935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223396 | REC_0013180 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 7.6 | 77 | female | 1 | 3 | 4.3 | 5 | pembrolizumab 200 mg q3w | 9.1 | true | MSS | 2026-03-15T05:36:00.284280+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575217 | REC_0013181 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 4.2 | 73 | female | 2 | 59 | 6.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.2 | true | MSS | 2026-03-15T05:36:00.284575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_885934 | REC_0013182 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 17 | 12.1 | 70 | male | 0 | 11 | 2 | 7 | sotorasib 960 mg daily | 10.5 | false | MSS | 2026-03-15T05:36:00.284860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696278 | REC_0013183 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 6.3 | 71 | female | 1 | 5 | 2.7 | 6 | osimertinib 80 mg daily | 10.4 | true | MSS | 2026-03-15T05:36:00.285316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_705198 | REC_0013184 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 9.2 | 73 | female | 0 | 18 | 5.3 | 6 | osimertinib 80 mg daily | 13.2 | true | MSS | 2026-03-15T05:36:00.285674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458680 | REC_0013185 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 11.8 | 62 | female | 1 | 16 | 5.4 | 2 | osimertinib 80 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:36:00.286024+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244289 | REC_0013186 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 3 | 65 | male | 1 | 61 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.9 | true | MSS | 2026-03-15T05:36:00.286361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364987 | REC_0013187 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 6.5 | 66 | female | 0 | 15 | 6.2 | 6 | sotorasib 960 mg daily | 13.2 | false | MSS | 2026-03-15T05:36:00.286696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252742 | REC_0013188 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 19.4 | 67 | female | 1 | 10 | 4.1 | 5 | osimertinib 80 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:36:00.288282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924157 | REC_0013189 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 12.4 | 71 | female | 1 | 10 | 4.5 | 1 | osimertinib 80 mg daily | 23.7 | false | MSI-H | 2026-03-15T05:36:00.288681+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_231732 | REC_0013190 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 16.8 | 66 | female | 1 | 13 | 6.6 | 4 | alectinib 600 mg BID | 9.8 | false | MSI-H | 2026-03-15T05:36:00.288990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_851436 | REC_0013191 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 18.5 | 67 | female | 1 | 9 | 5 | 6 | sotorasib 960 mg daily | 14 | false | MSI-H | 2026-03-15T05:36:00.289279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616661 | REC_0013192 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.3 | 70 | female | 0 | 13 | 5.4 | 8 | alectinib 600 mg BID | 11.7 | false | MSS | 2026-03-15T05:36:00.289577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315951 | REC_0013193 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 10.2 | 67 | female | 0 | 6 | 5.9 | 2 | sotorasib 960 mg daily | 12.4 | true | MSI-H | 2026-03-15T05:36:00.289888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235040 | REC_0013194 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 12.3 | 65 | female | 0 | 10 | 6.6 | 1 | osimertinib 80 mg daily | 19.9 | true | MSI-H | 2026-03-15T05:36:00.290190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955792 | REC_0013195 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7 | 66 | female | 0 | 59 | 5.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 7.7 | true | MSS | 2026-03-15T05:36:00.290493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_854256 | REC_0013196 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 11.3 | 69 | female | 0 | 17 | 5.6 | 6 | osimertinib 80 mg daily | 7.5 | false | MSI-H | 2026-03-15T05:36:00.290922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_703983 | REC_0013197 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 35 | 14.5 | 51 | female | 0 | 6 | 6.9 | 4 | osimertinib 80 mg daily | 7.5 | false | MSS | 2026-03-15T05:36:00.291261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560947 | REC_0013198 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 14 | 4.5 | 63 | male | 0 | 65 | 8.3 | 4 | pembrolizumab 200 mg q3w | 11.9 | false | MSS | 2026-03-15T05:36:00.291559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260778 | REC_0013199 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 16.8 | 63 | female | 1 | 8 | 3.8 | 2 | osimertinib 80 mg daily | 18.6 | true | MSI-H | 2026-03-15T05:36:00.291845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532218 | REC_0013200 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 11 | 64 | male | 1 | 7 | 5 | 8 | entrectinib 600 mg daily | 16.4 | false | MSI-H | 2026-03-15T05:36:00.292228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.